Ruben P A Van Eijk

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5809189/publications.pdf

Version: 2024-02-01

64 papers	1,788 citations	361296 20 h-index	315616 38 g-index
65 all docs	65 docs citations	65 times ranked	1997 citing authors

#	Article	IF	Citations
1	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	4.9	342
2	Hypermetabolism in ALS is associated with greater functional decline and shorter survival. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1016-1023.	0.9	177
3	Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology, 2017, 89, 1915-1922.	1.5	82
4	Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology, 2019, 92, .	1.5	66
5	Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 595-604.	1.1	63
6	Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 156-161.	0.9	62
7	Natural history of lung function in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2020, 15, 88.	1.2	56
8	Population-based analysis of survival in spinal muscular atrophy. Neurology, 2020, 94, e1634-e1644.	1.5	54
9	Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 867-875.	0.9	46
10	Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. Neurology, 2019, 93, e149-e158.	1.5	45
11	Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology, 2020, 95, e1988-e1998.	1.5	44
12	Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 75-81.	0.9	41
13	Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study. Journal of Neurology, 2019, 266, 2387-2395.	1.8	39
14	Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 497-505.	1.1	38
15	Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. Neurology, 2020, 94, e1470-e1479.	1.5	38
16	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 281.1-281.	0.9	33
17	Nerve ultrasound for diagnosing chronic inflammatory neuropathy. Neurology, 2020, 95, e1745-e1753.	1.5	32
18	Quantitative MRI of skeletal muscle in a crossâ€sectional cohort of patients with spinal muscular atrophy types 2 and 3. NMR in Biomedicine, 2020, 33, e4357.	1.6	31

#	Article	IF	Citations
19	An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 300-307.	1.1	30
20	Effect of Individual Surgeons and Anesthesiologists on Operating Room Time. Anesthesia and Analgesia, 2016, 123, 445-451.	1.1	29
21	Effect of Virtual Reality Gait Training on Participation in Survivors of Subacute Stroke: A Randomized Controlled Trial. Physical Therapy, 2021, 101, .	1.1	27
22	The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis. Annals of Neurology, 2020, 88, 796-806.	2.8	23
23	Evidence for a multimodal effect of riluzole in patients with ALS?. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1183-1184.	0.9	22
24	Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet Journal of Rare Diseases, 2020, 15, 75.	1.2	22
25	TRICALS: creating a highway toward a cure. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 496-501.	1.1	20
26	Correlates of Fatigability in Patients With Spinal Muscular Atrophy. Neurology, 2021, 96, e845-e852.	1.5	20
27	Aerobic Exercise Therapy in Ambulatory Patients With ALS: A Randomized Controlled Trial. Neurorehabilitation and Neural Repair, 2019, 33, 153-164.	1.4	19
28	Quantification of disease progression in spinal muscular atrophy with muscle MRIâ€"a pilot study. NMR in Biomedicine, 2021, 34, e4473.	1.6	19
29	Innovating Clinical Trials for Amyotrophic Lateral Sclerosis. Neurology, 2021, 97, 528-536.	1.5	19
30	Incidence, Prevalence, and Geographical Clustering of Motor Neuron Disease in the Netherlands. Neurology, 2021, 96, .	1.5	19
31	Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Current Opinion in Neurology, 2020, 33, 655-661.	1.8	17
32	A Road Map for Remote Digital Health Technology for Motor Neuron Disease. Journal of Medical Internet Research, 2021, 23, e28766.	2.1	16
33	Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-320998.	0.9	14
34	Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure?. Pharmacogenomics Journal, 2020, 20, 220-226.	0.9	14
35	Clinical outcomes in multifocal motor neuropathy. Neurology, 2020, 95, e1979-e1987.	1.5	13
36	Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study. Orphanet Journal of Rare Diseases, 2022, 17, 70.	1.2	12

#	Article	IF	Citations
37	Venous creatinine as a biomarker for loss of fatâ€free mass and disease progression in patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 3615-3625.	1.7	10
38	Characterising ALS disease progression according to El Escorial and Gold Coast criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 865-870.	0.9	10
39	Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. Clinical Neurophysiology, 2021, 132, 3152-3159.	0.7	9
40	Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs. Journal of Clinical Epidemiology, 2018, 98, 80-88.	2.4	8
41	Usefulness of a Double-Blind Placebo-Controlled Response Test to Demonstrate Rapid Onset Analgesia with Phenytoin 10% Cream in Polyneuropathy . Journal of Pain Research, 2020, Volume 13, 877-882.	0.8	8
42	Portable fixed dynamometry: towards remote muscle strength measurements in patients with motor neuron disease. Journal of Neurology, 2021, 268, 1738-1746.	1.8	8
43	Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF). Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 539-546.	0.9	8
44	Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 500-507.	1.1	8
45	Statins do not increase risk of polyneuropathy. Neurology, 2019, 92, e2136-e2144.	1.5	7
46	Novel Application of Postmortem CT Angiography for Evaluation of the Intracranial Vascular Anatomy in Cadaver Heads. American Journal of Roentgenology, 2015, 205, 1276-1280.	1.0	6
47	Two heads are better than one: benefits of joint models for ALS trials. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1071-1072.	0.9	6
48	Clinical relevance of testing for metabolic vitamin B12 deficiency in patients with polyneuropathy. Nutritional Neuroscience, 2022, 25, 2536-2546.	1.5	6
49	Frequent selfâ€assessments in ALS Clinical Trials: worthwhile or an unnecessary burden for patients?. Annals of Clinical and Translational Neurology, 2020, 7, 2074-2075.	1.7	5
50	Prognostic value of nerve ultrasonography: A prospective multicenter study on the natural history of chronic inflammatory neuropathies. European Journal of Neurology, 2021, 28, 2327-2338.	1.7	5
51	Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combineâ€”That is the Estimand. Clinical Pharmacology and Therapeutics, 2022, 111, 817-825.	2.3	5
52	Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy. Journal of Neurology, 2019, 266, 2734-2742.	1.8	4
53	Implications of spirometric reference values for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 473-480.	1.1	4
54	A placebo-controlled trial to investigate the safety and efficacy of Penicillin G/Hydrocortisone in patients with ALS (PHALS trial). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 584-592.	1.1	4

#	Article	IF	Citations
55	Motor unit reserve capacity in spinal muscular atrophy during fatiguing endurance performance. Clinical Neurophysiology, 2021, 132, 800-807.	0.7	4
56	Reconsidering the revised amyotrophic lateral sclerosis functional rating scale for ALS clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 569-570.	0.9	4
57	In pursuit of the normal progressor: the holy grail for ALS clinical trial design?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 1-2.	1.1	3
58	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.1	3
59	Relative hyperventilation in non-ventilated patients with spinal muscular atrophy. European Respiratory Journal, 2020, 56, 2000162.	3.1	2
60	Shortâ€term effect and effect on rate of lung function decline after surgery for neuromuscular or syndromic scoliosis. Pediatric Pulmonology, 2022, 57, 1303-1309.	1.0	2
61	Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials. Journal of Clinical Epidemiology, 2022, 147, 32-39.	2.4	2
62	Comment: Plateaus and reversals in ALS disease course or limitations of trial design?. Neurology, 2016, 86, 811-811.	1.5	1
63	The rise of innovative clinical trial designs: whatâ€™s in it for amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 3-4.	1.1	1
64	Pattern of muscle strength improvement after intravenous immunoglobulin therapy in multifocal motor neuropathy. Muscle and Nerve, 2021, 63, 678-682.	1.0	1